← All trials
NCT05415462
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 6, 2022
- Primary completion
- Aug 22, 2023
- Completion date
- Aug 22, 2023
- First posted
- Jun 13, 2022
- Last posted
- Sep 21, 2022
- Enrollment
- 6102
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Moderna TherapeuticsLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.